AbbVie’s Juvmo Won FDA Approval Three Days Before ICER Holds a Public Meeting on Its Value
AbbVie now has to name a price for Juvmo into a benchmark that ICER set before the drug was even approved.
AbbVie now has to name a price for Juvmo into a benchmark that ICER set before the drug was even approved.
An assessment body has priced a drug that has neither an approval nor a price. The number will sit in every payer negotiation that follows.
FB102’s entire human efficacy dataset in vitiligo is 42 patients, ten of them on placebo. argenx paid $2.2 billion in cash, with no milestones.